BRCA1/2 testing rates in epithelial ovarian cancer: a focus on the untested patients

BACKGROUND: Since 2015, Dutch guidelines have recommended BRCA1/2 pathogenic variant testing for all patients with epithelial ovarian cancer. Recently, recommendations shifted from germline testing to the tumor-first approach, in which tumor tissue is tested first, and subsequent germline testing is...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanjouw, Lieke, Mourits, Marian J E, Bart, Joost, ter Elst, Arja, Berger, Lieke P V, van der Hout, Annemieke H, Alam, Naufil, de Bock, Geertruida H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423510/
https://www.ncbi.nlm.nih.gov/pubmed/37137525
http://dx.doi.org/10.1136/ijgc-2023-004307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423510/
https://www.ncbi.nlm.nih.gov/pubmed/37137525
http://dx.doi.org/10.1136/ijgc-2023-004307

Ejemplares similares